VolitionRX Ltd. Announces First Quarter 2025 Financial Results and Business Update

HENDERSON, Nev., May 15, 2025 /PRNewswire/ – VolitionRx Limited (NYSE AMERICAN: VNRX), a pioneering epigenetics company, today announced its financial results and business update for the first quarter ended March 31, 2025. The company, known for its innovative Nu.Q® platform, is making significant strides in the human diagnostics market with its epigenetic cancer detection blood tests.

Financial Highlights and Business Developments

VolitionRx reported a notable increase in revenue, closing the quarter with $0.9 million, marking a 441.18% rise compared to the $0.2 million reported in the same quarter of the previous year. This impressive growth underscores the company’s expanding footprint in the diagnostics sector. Analysts had projected an earnings per share (EPS) of -0.043 USD, reflecting a significant improvement from the -0.100 USD EPS recorded in the same period last year.

Cameron Reynolds, President and Group Chief Executive Officer, emphasized the pivotal nature of 2025 for VolitionRx. “This year is crucial as we focus on commercializing our groundbreaking Nu.Q® platform,” Reynolds stated. “We are currently in confidential discussions with more than ten companies, with the combined market value of seven of these companies exceeding $600 billion. This highlights the substantial global potential and impact our technology could have.”

Upcoming Conference Call

To delve deeper into these results and discuss future prospects, VolitionRx management will host a conference call on Friday, May 16, at 8:30 a.m. U.S. Eastern Time. The call will provide an opportunity for investors and analysts to gain insights into the company’s strategic direction and operational achievements.

Market Outlook

Looking ahead, analysts project a continued trajectory of growth for VolitionRx. For the current fiscal year, estimates suggest a potential revenue of $7.5 million, a significant increase from the $1.2 million reported in the previous year. Despite expectations of a continued loss per share, averaging -0.134 USD, the company’s strategic initiatives and partnerships are anticipated to drive long-term value creation.

VolitionRx’s focus on commercializing its Nu.Q® platform positions it at the forefront of the epigenetics industry, with the potential to revolutionize cancer diagnostics. As the company navigates through 2025, its efforts to expand its market reach and solidify its technological leadership are expected to yield substantial returns for stakeholders.

For more information on the conference call and to stay updated on VolitionRx’s progress, interested parties are encouraged to follow the company’s announcements and participate in the upcoming discussion.